Centre for Bacterial Resistance Biology, Department of Life Sciences, Imperial College London, London SW7 2AZ, UK.
Centre for Bacterial Resistance Biology, Department of Infectious Disease, Imperial College London, London SW7 2AZ, UK.
Microbiology (Reading). 2023 Aug;169(8). doi: 10.1099/mic.0.001377.
The human gut microbiota can restrict the growth of pathogens to prevent them from colonizing the intestine ('colonization resistance'). However, antibiotic treatment can kill members of the gut microbiota ('gut commensals') and reduce competition for nutrients, making these nutrients available to support the growth of pathogens. This disturbance can lead to the growth and expansion of pathogens within the intestine (including antibiotic-resistant pathogens), where these pathogens can exploit the absence of competitors and the nutrient-enriched gut environment. In this review, we discuss nutrient competition between the gut microbiota and pathogens. We also provide an overview of how nutrient competition can be harnessed to support the design of next-generation microbiome therapeutics to restrict the growth of pathogens and prevent the development of invasive infections.
人类肠道微生物群可以限制病原体的生长,防止它们在肠道中定植(“定植抗性”)。然而,抗生素治疗会杀死肠道微生物群的成员(“肠道共生体”),减少对营养物质的竞争,使这些营养物质可供支持病原体的生长。这种干扰会导致肠道内病原体的生长和扩张(包括抗生素耐药性病原体),这些病原体可以利用缺乏竞争者和富含营养的肠道环境。在这篇综述中,我们讨论了肠道微生物群和病原体之间的营养竞争。我们还概述了如何利用营养竞争来支持下一代微生物组治疗药物的设计,以限制病原体的生长并防止侵袭性感染的发展。